CD274 and non-small cell lung carcinoma: Inspired by the superiority of nivolumab-ipilimumab over chemotherapy in PD-L1-positive patients in CheckMate 227, CheckMate 9LA targeted treatment-naïve WT NSCLC patients, regardless of histology and PD-L1 expression.